Skip to main content
SpringerLink
Log in

Role of FDG-PET/CT in staging and first-line treatment of Hodgkin and aggressive B-cell lymphomas

  • review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Abstract

Positron emission tomography with integrated computed tomography (PET/CT) is increasingly used for the initial staging, final or even interim (mid-treatment) response assessment in malignant lymphomas. Extensive clinical experience has been gained with Hodgkin lymphoma (HL) and aggressive B-cell non-Hodgkin lymphomas, including diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMLBCL) and other subtypes, which are the subject of the present review. The use of PET/CT is now considered mandatory for baseline staging in these entities, providing more accurate information and obviating the need of bone marrow biopsy (BMB) at least in HL. PET/CT has been the long-standing “gold standard” for final response assessment. Furthermore, early interim PET evaluation provides valuable prognostic information in HL and DLBCL. In HL, it appears that treatment intensification with Bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone (BEACOPP)-escalated can improve disease control in patients with persistent PET positivity after two cycles of ABVD. However, there is no randomized evidence of survival benefit as yet. In contrast, regimens effective in overcoming the adverse impact of persistent PET positivity have not been yet described in DLBCL. The 2014 recommendations suggest the use of PET/CT for baseline staging and final response assessment in all [18F]fluorodeoxyglucose (FDG)-avid lymphoma subtypes, including the above named ones. The use of interim evaluation is not considered fully documented yet. The exact role of PET/CT in guiding treatment decisions has to be defined by ongoing and future randomized trials and evidence-based approaches are expected to become available in the near future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.

    Article  PubMed  Google Scholar 

  2. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Lister TA, et al. Recommendations for the initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–67.

    Article  PubMed  Google Scholar 

  3. Barrington SF, Mikhaeel GN, Kostakoglu L, Meignan M, Hutchings M, Müeller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048–58.

  4. Hutchings M. How does PET/CT help in selecting therapy for patients with Hodgkin lymphoma? Hematology 2012, Am Soc Hematol Educ Programm Book. 2012. pp 322–327.doi: 10.1182/asheducation-2012.1.322.

    Google Scholar 

  5. Sehn LH, Klasa R, Shenkier T, Villa D, Slack GW, Gascoyne RD, et al. Long-term experience with PET-guided consolidative radiation therapy (XRT) in patients with advanced stage diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP. Hematol Oncol. 2013;31(S1):137. (abstr 123).

    Google Scholar 

  6. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–91.

    Article  CAS  PubMed  Google Scholar 

  7. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomized controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105–16.

    Article  CAS  PubMed  Google Scholar 

  8. Paone G, Itti E, Haioun C, et al. Bone marrow involvement in diffuse large B-cell lymphoma: Correlation between FDG-PET uptake and type of cellular infiltrate. Eur J Nucl Med Mol Imaging. 2009;36:745–50.

    Article  PubMed  Google Scholar 

  9. Vassilakopoulos TP, Pangalis GA, Katsigiannis A, et al. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care. Oncologist. 2012;17:239–49.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Martelli M, Ceriani L, Zucca E, Zinzani PL, Ferreri AJ, Vitolo U, et al. [18F] fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 study. J Clin Oncol. 2014;32:1769–75.

    Article  PubMed  Google Scholar 

  11. El-Galaly TC, d’ Amore F, Mylam KJ, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naïve patients with Hodgkin lymphoma. J Clin Oncol. 2012;30:4508–14.

    Article  PubMed  Google Scholar 

  12. Vassilakopoulos TP, Angelopoulou MK, Constantinou N, et al. Development and validation of a clinical prediction rule for bone marrow involvement in patients with Hodgkin lymphoma. Blood. 2005;105:1875–80.

    Article  CAS  PubMed  Google Scholar 

  13. Adams HJ, Kwee TC, de Keizer B, Fijnheer R, de Klerk JM, Littooij AS, et al. Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary? Ann Oncol. 2014;25:921–7.

    Article  CAS  PubMed  Google Scholar 

  14. Vassilakopoulos TP, Rondogianni P, Prassopoulos V, Chatziioannou S, Moschogiannis M, Poziopoulos C, et al. Comparative assessment of bone marrow involvement (BMI) by bone marrow biopsy (BMB) or positron emission tomography/computed tomography (PET/CT) in Hodgkin lymphoma (HL). Haematologica. 2014;99(Suppl 1):401 (abstr. 1050).

    Google Scholar 

  15. Sehn LH, Scott DW, Chhanabhai M, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2011;29:1452–7.

    Article  PubMed  Google Scholar 

  16. Adams HJA, Kwee TC, Finjnheer R, Dubois SV, Nievelstein AJR, de Klerk JMH. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma. Am J Hematol. 2014;89:726–31.

    Article  CAS  PubMed  Google Scholar 

  17. Hong J, Lee Y, Park Y, et al. Role of FDG-PET/CT in detecting lymphomatous bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma. Ann Hematol. 2012;91:687–95.

    Article  CAS  PubMed  Google Scholar 

  18. Cerci JJ, Gyorke T, Fanti S, Paez D, Meneghetti JC, Redondo F, et al. Combined PET and biopsy evidence of marrow involvement improves prognostic prediction in diffuse large B-cell lymphoma. J Nucl Med. 2014;55:1591–7.

    Article  PubMed  Google Scholar 

  19. Berthet L, Cochet A, Kanoun S, Berriolo-Riedinger A, Humbert O, Toubeau M, et al. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy. J Nucl Med. 2013;54:1244–50.

    Article  CAS  PubMed  Google Scholar 

  20. Khan AB, Barrington SF, Mikhaeel NG, Hunt AA, Cameron L, Morris T, et al. PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. Blood. 2013;122:61–7.

    Article  CAS  PubMed  Google Scholar 

  21. Adams HJA, Kwee TC. Do not abandon the bone marrow biopsy yet in diffuse large B-cell lymphoma. J Clin Oncol. 2015. doi:10.1200/JCO.2014.58.7360. (Epub 17 Feb 2015).

  22. Meignan M, Itti E, Gallamini A, Younes A. FDG PET/CT imaging as a biomarker in lymphoma. Eur J Nucl Med Mol Imaging. 2015. doi:10.1007/s00259-014-2973-6. (Epub 09 Jan 2015).

  23. Kanoun S, Rossi C, Berriolo-Riedinger A, Dygai-Cochet I, Cochet A, Humbert O, et al. Baseline metabolic tumor volume is an independent prognostic factor in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1735–43.

    Article  PubMed  Google Scholar 

  24. Song MK, Chung JS, Lee JJ, Jeong SY, Lee SM, Hong JS, et al. Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin’s lymphoma. Cancer Sci. 2013;104:1656–61.

    Article  CAS  PubMed  Google Scholar 

  25. Sasanelli M, Meignan M, Haioun C, Berriolo-Riedinger A, Casasnovas RO, Biggi A, et al. Pretherapy metabolic tumor volume is an independent predictor of outcome in diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:2017–22.

    Article  CAS  PubMed  Google Scholar 

  26. Song MK, Chung JS, Shin HJ, Lee SM, Lee SE, Lee HS, et al. Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann Hematol. 2012;91:697–703.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Kim TM, Paeng JC, Chun IK, Keam B, Jeon YK, Lee SH, et al. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the international prognostic index for patients with diffuse large B cell lymphoma. Cancer. 2013;119:1195–202.

    Article  CAS  PubMed  Google Scholar 

  28. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571–8.

    Article  PubMed  Google Scholar 

  29. Vassilakopoulos TP, Pangalis GA, Boutsikas G, et al. Prognostic factors in patients with Hodgkin lymphoma (HL) and a negative PET/CT after ABVD chemotherapy: potential applications for the design of follow-up strategies. Haematologica. 2012;97(Suppl 1):87. (abstr. 218).

    Google Scholar 

  30. Radford J, Illidge T, Counsell L, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015;372:1598–607.

    Article  PubMed  Google Scholar 

  31. Hartridge-Lambert SK, Schoder H, Lim RC, Maragulia JC, Portlock CS. ABVD alone and a PET scan complete remission negates the need for radiologic surveillance in early-stage, nonbulky Hodgkin lymphoma. Cancer. 2013;119:1203–9.

    Article  CAS  PubMed  Google Scholar 

  32. Sher DJ, Mauch PM, van den Abbeele A, LaCasce AS, Czerminski J, Ng AK. Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin’s lymphoma: the importance of involved field radiotherapy. Ann Oncol. 2009;20:1848–53.

    Article  CAS  PubMed  Google Scholar 

  33. Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379:1791–9.

    Article  CAS  PubMed  Google Scholar 

  34. Barnes JA, LaCasce AS, Zukotynski K, et al. End-of-treatment but not interim PET scan predicts outcome in nonbulky limited stage Hodgkin’s lymphoma. Ann Oncol. 2011;22:910–5.

    Article  CAS  PubMed  Google Scholar 

  35. Vassilakopoulos TP, Rontogianni P, Pangalis GA, et al. Outcome and prognostic factors in patients with Hodgkin lymphoma (HL) who remain PET/CT-positive after ABVD combination chemotherapy: potential applications for the design of subsequent treatment. Haematologica. 2012;97(Suppl 1):562 (abstr. 1404).

    Google Scholar 

  36. Kobe C, Kuhnert G, Kahraman D, Haverkamp H, Eich HT, Franke M, et al. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma. J Clin Oncol. 2014;32:1776–81.

    Article  PubMed  Google Scholar 

  37. Picardi M, De Renzo A, Pane F, et al. Randomized comparison of consolidation radiation versus observation in bulky Hodgkin’s lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma. 2007;48:1721–7.

    Article  PubMed  Google Scholar 

  38. Raemaekers JM, André MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014;32:1188–94.

    Article  PubMed  Google Scholar 

  39. Illidge T. Radiotherapy in early stage Hodgkin lymphoma. Hematol Oncol. 2013;31(Suppl 1):92–5.

    Article  PubMed  Google Scholar 

  40. Vassilakopoulos TP, Pangalis GA, Chatziioannou S, et al. PET/CT in patients with primary mediastinal large B-cell lymphoma responding to Rituximab-CHOP: an analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy. Leukemia. 2015. doi: 10.1038/leu.2015.120.

  41. Martelli M, Ceriani L, Zucca E, et al. [18F] fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 study. J Clin Oncol. 2014;32:1769–75.

    Article  PubMed  Google Scholar 

  42. Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368:1408–16.

    Article  CAS  PubMed  Google Scholar 

  43. Filippi AR, Piva C, Giunta F, et al. Radiation therapy in primary mediastinal B-cell lymphoma with positron emission tomography positivity after rituximab chemotherapy. Int J Radiat Oncol Biol Phys. 2013;87:311–6.

    Article  CAS  PubMed  Google Scholar 

  44. Vassilakopoulos TP, Pangalis GA, Polliack A. A “PET” topic in primary mediastinal large B-cell lymphoma: positive or negative, and how to handle it in the end. Leuk Lymphoma. 2015;56:3–5.

    Article  PubMed  Google Scholar 

  45. Martelli M, Zucca E, Gospodarowicz M, Johnson PWM, Ricardi U. A randomized, multicentre, two-arm phase III comparative study assessing the role of mediastinal radiotherapy after rituximab-containing chemotherapy regimens to patients with newly diagnosed primary mediastinal large B-cell lymphoma (PMLBCL): the IELSG-37 study. Hematol Oncol. 2013;31(S1):140.

    Google Scholar 

  46. Dupuis J, Itti E, Rahmouni A, Hemery F, et al. Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. Ann Oncol. 2009;20:503–7.

    Article  CAS  PubMed  Google Scholar 

  47. Dabaja BS, Phan J, Mawlawi O, Medeiros LJ, Etzel C, Liang FW, et al. Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma. Leuk Lymphoma. 2013;54:2631–8.

    Article  CAS  PubMed  Google Scholar 

  48. Vassilakopoulos TP, Kanellopoulos A, Papageorgiou S, Pangalis GA, Anastasopoulou A, Moschogianni M, et al. Clinical implications and prognostic significance of positron emission tomography (PET/CT) in patients with diffuse large B-cell lymphoma (DLBCL) after R-CHOP chemoimmunotherapy. Haematologica. 2014;99(Suppl 1): 702. (abstr. 1831).

    Google Scholar 

  49. Thomas A, Gingrich RD, Smith BJ, et al. 18-fluoro-deoxyglucose positron emission tomography report interpretation as predictor of outcome in diffuse large B-cell lymphoma including analysis of “indeterminate” reports. Leuk lymphoma. 2010;51:439–46.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  50. Sehn LH, Klasa R, Shenkier T, Villa D, Slack GW, Gascoyne RD, et al. Long-term experience with PET-guided consolidative radiation therapy (XRT) in patients with advanced stage diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP. Hematol Oncol. 2013;31(S1):137. (abstr. 123).

    Google Scholar 

  51. Pregno P, Chiappella A, Bello M, Botto B, Ferrero S, Franceschetti S, et al. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood. 2012;119:2066–73.

    Article  CAS  PubMed  Google Scholar 

  52. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107:52–9.

    Article  CAS  PubMed  Google Scholar 

  53. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746–52.

    Article  CAS  PubMed  Google Scholar 

  54. Itti E, Juweid ME, Haioun C, et al. Improvement of early 18F-FDG-PET interpretation in diffuse large B-cell Lymphoma: importance of the reference background. J Nucl Med. 2010;51:1857–62.

    Article  PubMed  Google Scholar 

  55. Moskowitz CH, Schoder H, Teruya-Feldstein J, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol. 2010;28:1896–903.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  56. Avigdor A, Sirotkin T, Kedmi M, Ribakovsy E, Berkowicz M, Davidovitz Y, et al. The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma. Ann Hematol. 2014;93:1297–304.

    Article  CAS  PubMed  Google Scholar 

  57. Gallamini A, Barrington SF, Biggi A, Chauvie S, Kostakoglou L, Gregianin M, et al. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica. 2014;99:1107–13.

    Article  PubMed Central  PubMed  Google Scholar 

  58. Biggi A, Gallamini A, Chauvie S, Hutchings M, Kostakoglu L, Gregianin M, et al. International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: Interpretation criteria and concordance rate among reviewers. J Nucl Med. 2013;54:683–90.

    Article  CAS  PubMed  Google Scholar 

  59. Kostakoglu L, Schoder H, Johnson JL, et al. Interim FDG PET imaging in stage I/II non bulky Hodgkin lymphoma: would using combined PET and CT criteria better predict response than each test alone? Leuk Lymphoma. 2012;53:2143–50.

    Article  CAS  PubMed  Google Scholar 

  60. Oki Y, Chuang H, Chasen B, Jessop A, Pan T, Fanale M, et al. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol. 2014;165:112–6.

    Article  CAS  PubMed  Google Scholar 

  61. Rigacci L, Puccini B, Zinzani PL, Biggi A, Castagnoli A, Merli F, et al. The prognostic value of positron emission tomography performed after two courses (interim-pet) of standard therapy on treatment outcome in early stage Hodgkin lymphoma. A multicentric study by the Fondazione Italiana Linfomi (FIL). Am J Hematol. 2015. doi:10.1002/ajh.23994.

  62. Gallamini A, Patti C, Viviani S, et al. Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol. 2011;152:551–60.

    Article  PubMed  Google Scholar 

  63. Press O, Li H, Schoder H, LeBlanc M, Rimsza L, Friedberg JW, et al. Response-adapted therapy of stage III-IV Hodgkin lymphoma based on interim FDG-PET imaging: early results of US Intergroup S0816. Haematologica. 2013;98(S2):36. (abstr. T108).

    Google Scholar 

  64. Johnson P, Federico M, Fossa A, O’ Doherty M, Roberts T, Stevens L, et al. Responses and chemotherapy dose adjustment determined by PET-CT imaging: first results from the international response adapted therapy in advanced Hodgkin lymphoma (RATHL) study. Hematol Oncol. 2013;31(S1):138. (abstr. 126).

    Article  Google Scholar 

  65. Markova J, Kobe C, Skopalova M, et al. FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced stage Hodgkin’s lymphoma has a high negative predictive value. Ann Oncol. 2009;20:1270–4.

    Article  CAS  PubMed  Google Scholar 

  66. Borchmann P, Haverkamp H, Lohri A, Kreissl S, Greil R, Markova J, et al. Addition of rituximab to BEACOPP escalated to improve the outcome of early interim PET positive advanced stage Hodgkin lymphoma patients: second planned interim analysis of the HD18 study. Blood. 2014;124:Abstract 500. (ASH Annual Meeting Abstracts).

  67. Vassilakopoulos TP, Angelopoulou MK, Rondogianni P, et al. Interim PET-Scan for early response assessment and potential modification of treatment plan after 2 ABVD cycles in advanced stage Hodgkin Lymphoma (HL). Haematologica. 2011;96(Suppl 2):abstr 322.

  68. Cimino G, Zaucha JM, Cirillo S, Saviolo C, Hutchings M, El-Galaly TC, et al. The complementary prognostic role of baseline and interim PET in predicting treatment outcome in advanced-stage Hodgkin lymphoma. Blood. 2014;124:Abstract 4405. (ASH Annual Meeting Abstracts).

  69. Agostinelli C. A clinical-pathological algorithm based on the combination of interim PET with biological markers in classical Hodgkin lymphoma. Presented at the Fifth International Workshop on PET in Lymphoma, Menton, 19–20 September 2014. http://eitti.free.fr.

  70. Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;20:4548–54.

    Article  Google Scholar 

  71. Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379:1791–9.

    Article  CAS  PubMed  Google Scholar 

  72. von Tresckow B, Plütschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol. 2012;30:907–13.

    Article  Google Scholar 

  73. Rossi C, Kanoun S, Berriolo-Riedinger A, Dygai-Cochet I, Humbert O, Legouge C, et al. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients. J Nucl Med. 2014;55:569–73.

    Article  CAS  PubMed  Google Scholar 

  74. Moskowitz C, Hamlin PA, Maragulia J, Meikle J, Zelenetz AD. Sequential dose-dense RCHOP followed by ICE consolidation (MSKCC protocol 01-142) without radiotherapy for patients with primary mediastinal large B-cell lymphoma. Blood. 2010;116:abstr 420.

  75. Horning SJ, Juweid ME, Schoeder H, et al. Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood. 2010;115:775–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  76. Meignan M, Gallamini A, Itti E, Barrington S, Haioun C, Polliack A. Report on the third international workshop on interim positron emission tomography in lymphoma held in Menton, France, 26–27 September 2011 and Menton 2011 consensus. Leuk Lymphoma. 2012;53:1876–81.

    Article  PubMed  Google Scholar 

  77. Carr R, Fanti S, Paez D, Cerci J, Gyorke T, Redondo F, et al. Prospective international cohort study demonstrates inability if interim PET to predict treatment failure in diffuse large B-cell lymphoma. J Nucl Med. 2014;55:1936–44.

    Article  PubMed  Google Scholar 

  78. Itti E, Meignan M, Berriolo-Riedinger A, Biggi A, Cashen AF, Verra P, et al. An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and DSUVmax. Eur J Nucl Med Mol Imaging. 2013;40:1312–20.

    Article  PubMed  Google Scholar 

  79. Casasnovas RO, Meignan M, Berriolo-Riedinger A, et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood. 2011;118:37–43.

    Article  CAS  PubMed  Google Scholar 

  80. Dührsen U, Hüttmann A, Jöckel KH, Müller S. Positron emission tomography guided therapy of aggressive non-Hodgkin lymphomas–the PETAL trial. Leuk Lymphoma. 2009;50:1757–60.

    Article  PubMed  Google Scholar 

  81. Duehrsen U, Hüttmann A, Müller S, Hertenstein B, Kotzerke J, Mesters R, et al. Positron emission tomography (PET) guided therapy of aggressive lymphomas—a randomized controlled trial comparing different treatment approaches based on interim PET results (PETAL Trial). Blood. 2014;124:Abstract 391. (ASH Annual Meeting Abstracts).

  82. Swinnen LJ, Li H, Quon A, Gascoyne RD, Ranheim EA, Hong F, et al. Response-adapted therapy and predictive value of mid-treatment PET scanning for diffuse large B-cell lymphoma. ECOG study E3404. Hematol Oncol. 2013;31(S1):138 (abstr. 126). (101 (abstr. 016)).

    Google Scholar 

  83. Sickinger MT, von Tresckow B, Kobe C, Engert A, Borchmann P, Skoetz N. Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma. Cochrane Database Syst Rev. 2015;1:CD010533. doi:10.1002/14651858.CD010533.pub2.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, School of Medicine, Laikon General Hospital, National and Kapodistrian University of Athens, 17 Agiou Thoma Str., Goudi, 11527, Athens, Greece

    Theodoros P. Vassilakopoulos MD, PhD,  Kostas Konstantopoulos MD, PhD &  Maria K. Angelopoulou MD, PhD

  2. Department of Nuclear Medicine and PET/CT, HYGEIA Hospital, 20 Pefkon Str., AgiosStefanos, 14565, Athens, Greece

    Vassilios Prassopoulos MD

  3. Department of Nuclear Medicine and PET/CT, Evangelismos General Hospital, 45–47 Ipsilantou Str., 11576, Athens, Greece

    Phoivi Rondogianni MD, FENMB

  4. Centre for Clinical and Translational Research, Biomedical Research Foundation of the Academy of Athens, 4 Soranou Ephessiou Street, 11527, Athens, Greece

    Sofia Chatziioannou MD, PhD

Authors
  1. Theodoros P. Vassilakopoulos MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vassilios Prassopoulos MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Phoivi Rondogianni MD, FENMB
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sofia Chatziioannou MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kostas Konstantopoulos MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maria K. Angelopoulou MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Theodoros P. Vassilakopoulos MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vassilakopoulos, T., Prassopoulos, V., Rondogianni, P. et al. Role of FDG-PET/CT in staging and first-line treatment of Hodgkin and aggressive B-cell lymphomas. memo 8, 105–114 (2015). https://doi.org/10.1007/s12254-015-0215-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-015-0215-7

Keywords

Search

Navigation